GE HealthCare announces intent to establish MAGNUS Neuro Alliance to unlock new possibilities in MRI for neuroscience
- Alliance intends to bring together leading neuroscience researchers to explore high-performance MR imaging and new approaches to studying the brain
- Members will collaborate to explore advanced MR techniques and research applications leveraging an ultra high-gradient head-only MR system
Neurological conditions affect more than 3 billion people globally – over one in three people worldwide3. Yet only a fraction can be diagnosed by MRI, highlighting a critical need to expand the neurological clinical applications of MRI. The group, gathering today for the first time while also attending the 5th High Performance Neuroimaging Symposium at the
“Bringing together leading neuroscience researchers allows us to create a collaborative environment where new questions, methods and discoveries can emerge,” said
Advancing research through collaboration
As part of the Alliance, current and future MAGNUS users at
- Advancing understanding of how neurological disease manifests and progresses in the brain
- Identifying and characterizing subtle changes in brain structure, function and biology associated with disease
- Developing new imaging technologies, techniques and biomarkers to investigate neurological disease
- Exploring new ways to detect, measure and characterize disease-related changes in the brain
“By bringing together neuroscientists with different perspectives and areas of expertise, this consortium creates an opportunity to tackle some of the most challenging questions in neuroscience collectively,” said
Research investigations aim to drive real-world outcomes
The unique design of ultra-high-gradient, head-only MRI aims to open new frontiers in neuroscience and clinical research. By pairing exceptional gradient performance with a dedicated head-only form factor, these research systems are designed to give researchers sensitivity and resolution to help reveal the brain’s finest structures in precise detail.
Leading institutions leveraging this technology are working across a growing range of research areas, including:
- Microstructural imaging, probing tissue architecture at scales at the cellular level
- Neurodegenerative disease, tracking subtle changes that may signal early disease
- Oncology, characterizing brain tumors and their surrounding tissue more precisely
- Traumatic brain injury, identification of reliable biomarkers
- Sleep research, exploring the brain's structure and function across sleep-wake states
- Multiple sclerosis, assessing disease progression through advanced biomarkers
- Psychiatric illness, investigating the neural correlates of mental health conditions
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world’s most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Advanced Imaging Solutions, Pharmaceutical Diagnostics and Patient Care Solutions segments to help clinicians deliver more personalized, precise patient care. We are a $20.6 billion business with approximately 54,000 colleagues working to create a world where healthcare has no limits.
GE HealthCare is proud to be among 2026 Fortune World’s Most Admired Companies™.
Follow us on LinkedIn, Facebook, Instagram, or visit our website for our latest news and perspectives.
|
1 Technology in Development. Not cleared or approved by the |
|
2 MAGNUS (Mesoscale diffusion with Advanced Gradients for Neuro Ultrafast Scanning) |
|
3 World Health Organization Global status report on neurology, 2025. https://www.who.int/publications/i/item/B09657. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20261110810797/en/
GE HealthCare Media Contact:
M +1 262 512 5281
katherine.scrivano@gehealthcare.com
Source: